Skip to Content


In the US, Nilotinib (nilotinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Chronic Myelogenous Leukemia.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Tyrosine kinase inhibitor

Chemical Names

4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide (WHO)

4-Methyl-N-[3-(4-methylmidazol-1-yl)-5-trifluormethylphenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamin)benzamid (IUPAC)

Foreign Names

  • Nilotinibum (Latin)
  • Nilotinib (German)
  • Nilotinib (French)
  • Nilotinib (Spanish)

Generic Names

  • Nilotinib (OS: BAN)
  • AMN-107 (IS: Novartis)

Brand Names

  • Tasigna
    Novartis, China; Novartis, Georgia; Novartis, Hong Kong; Novartis, Israel; Novartis, Malaysia; Novartis, Portugal; Novartis, Romania; Novartis, Singapore; Novartis, Slovenia; Novartis, Tunisia; Novartis, Turkey; Novartis, Taiwan; Novartis Farmaceutica, Spain; Novartis Healthcare, Philippines; Novartis, Australia; Novartis, Belgium; Novartis, Canada; Novartis, Switzerland; Novartis, Chile; Novartis, Czech Republic; Novartis, Germany; Novartis, Denmark; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Greece; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Iceland; Novartis, Japan; Novartis, South Korea; Novartis, Lithuania; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Serbia; Novartis, Sweden; Novartis, Thailand; Novartis, United States; Novartis, South Africa; Novartis Europharm, Austria; Novartis Europharm Limited, Latvia; Novartis Farma, Italy

International Drug Name Search


BANBritish Approved Name
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.